The relationship between urotensin II and its receptor and the clinicopathological parameters of breast cancer.
The relationship between urotensin II and its receptor and the clinicopathological parameters of breast cancer.
复制标题
DOI：
10.12659/msm.890459
复制
发表时间：
2014-08-12
期刊：
影响因子：
--
通讯作者：
Camci C
中科院分区：
文献类型：
--
作者：
Balakan O;Kalender ME;Suner A;Cengiz B;Oztuzcu S;Bayraktar R;Borazan E;Babacan T;Camci C
尾加压素II是一种血管活性多肽。已知一些血管活性多肽是由肿瘤细胞产生和分泌的，具有旁分泌生长刺激剂的作用。本研究的目的是探讨乳腺癌中尾加压素II及其受体信使RNA表达的关系。59名患有乳腺癌的女性参与了这项研究。中位年龄为48岁。分析新鲜乳腺癌组织及癌旁正常乳腺组织中尾加压素II及其受体mRNA的表达与临床病理参数的关系。59例乳腺癌组织中55例和59例正常乳腺组织中55例表达尾加压素II及其受体。尾加压素II与其受体呈显著正相关(p=0.001，r=0.632)，与年龄呈负相关(p=0.038，r=−0.281)。与绝经后组相比，绝经前组的尾加压素II水平更高(p<；0.05)。Urotensin II受体在绝经前组的平均表达高于绝经后组，在无结外侵袭组的表达也高于有结外侵袭组(P=0.001)。无淋巴管侵犯组的尾加压素II水平高于有淋巴管浸润组(p=0.048)。这项研究在英文医学文献中首次确定了乳腺癌组织中尾加压素II及其受体的mRNA表达。因此，尾加压素II似乎与绝经状态、结外侵犯和淋巴侵犯有关。
Urotensin II is a vasoactive polypeptide. It is known that some vasoactive polypeptides are produced and secreted by tumor cells, and act as a paracrine growth stimulant. The aim of this study was to examine the relationship between urotensin II and its receptor’s messenger RNA expression in breast cancer. Fifty-nine women with breast cancer were included in this study. The median age was 48 years. The relationships between urotensin II and urotensin II receptor mRNA expressions, which were derived from fresh breast cancer tissues and adjacent normal breast tissues, and clinical and pathological parameters, were assessed. We found expressions of urotensin II mRNA and its receptor in 55 of 59 breast cancer tissues and in 55 of 59 normal breast tissues. We found a positive significant correlation between urotensin II and its receptor (p=0.001, r=0.632), and found a negative, but insignificant, correlation between urotensin II and age (p=0.038, r=−0.281). Urotensin II levels were higher in the premenopausal group compared to the postmenopausal group (p<0.05). The mean urotensin II receptor expression was higher in the premenopausal group (p<0.05) compared to the postmenopausal group, and its expression was also higher in the group without extra-nodal invasion compared to that of the group with extra-nodal invasion (p=0.001). Urotensin II levels were higher in the group without lymphatic invasion compared to the group with lymphatic invasion (p=0.048). This study is the first in the English medical literature to determine the urotensin II and its receptor mRNA expressions in breast cancer tissues. Consequently, urotensin II seems be associated with menopausal status, and extra-nodal and lymphatic invasion.